1. Academic Validation
  2. Hydrophilic Sequence-Defined Cross-Linkers for Antibody-Drug Conjugates

Hydrophilic Sequence-Defined Cross-Linkers for Antibody-Drug Conjugates

  • Bioconjug Chem. 2019 Nov 20;30(11):2982-2988. doi: 10.1021/acs.bioconjchem.9b00713.
Joshua A Walker 1 Michelle R Sorkin 1 Francis Ledesma 1 Sneha R Kabaria 1 Robyn M Barfield 2 David Rabuka 2 Christopher A Alabi 1
Affiliations

Affiliations

  • 1 Robert Frederick Smith School of Chemical and Biomolecular Engineering , Cornell University , 113 Ho Plaza , Ithaca , New York 14850 , United States.
  • 2 Catalent Biologics , 5703 Hollis Street , Emeryville , California 94608 , United States.
Abstract

Antibody-drug conjugates (ADCs) are an established modality for the tissue-specific delivery of chemotherapeutics. However, due to the hydrophobic nature of many cytotoxic payloads, challenges remain in developing chemically stable ADCs with high drug loading. In previous studies, payload structure, unique stimuli-responsive chemistries, and PEGylated cross-linkers have been used to decrease ADC hydrophobicity. In this work, we investigate the effect of a new parameter, cross-linker sequence. A support-free synthesis of PEGylated, sequence-defined cross-linkers was developed and applied to the synthesis of three constitutionally isomeric ADCs containing PEG side chains and a monomethyl Auristatin E payload. Placement of PEG side chains distally from the payload was found to yield an ADC with altered hydrophilicity, antigen binding, and in vitro potency. This work establishes a versatile method for synthesizing multifunctional cross-linkers and identifies cross-linker sequence as a new handle for modulating the performance of ADCs.

Figures
Products